Reading the annual reports…

First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.

GSK plc (GSK) financial health, profit and balance sheet · Scorvest

GSK · NYSE · United States · Pharmaceutical Preparations

GSK plc

London · Fiscal year ends in December 2025 · Figures in GBP

+ Add to watchlist Compare

In shortGSK plc is profitable, generates cash and carries moderate debt, with revenue growing (+4.1% last year).

Financial health

Strong

Built from five areas over the last five annual reports. Tap an area to see the figures behind it.

How is this score calculated? →

Profitability97

Operating marginShare of each sale left after running the business, before interest and tax.	24.3%	98/100
Net marginShare of each sale left as profit after every cost, interest and tax.	17.5%	90/100
Return on equityProfit earned on the money shareholders put in. Above 15% is strong.	38.0%	100/100
Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge.	19.8%	100/100

Weight in the score: 25%

Balance sheet45

Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash.	0.82×	2/100
Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted.	1.08×	51/100
Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable.	1.40×	74/100
Interest coverageHow many times operating profit covers interest. Below 2 is risky.	11.32×	93/100
Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress.	1.38	7/100

Weight in the score: 25%

Cash generation99

Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt.	19.6%	98/100
Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy.	1.12×	100/100
Years with positive free cash flow (last 5)	5 of 5	100/100

Weight in the score: 20%

Stability88
Profitable years (last 5) 5 of 5 100/100
Years of revenue decline (last 5) 0 of 5 100/100
Revenue growth volatility 7.1% 85/100
Operating margin volatility 4.6% 67/100
Weight in the score: 20%
Growth19
Revenue growth, 3-year average 3.7% 37/100
EPS growth, 3-year average -27.6% 0/100
Weight in the score: 10%

Profitable years (last 5)	5 of 5	100/100
Years of revenue decline (last 5)	0 of 5	100/100
Revenue growth volatility	7.1%	85/100
Operating margin volatility	4.6%	67/100

Revenue growth, 3-year average	3.7%	37/100
EPS growth, 3-year average	-27.6%	0/100

Fiscal year 2025 · change vs prior year

Revenue: £32.7B; ▲ 4.1%
Net income: £5.7B; ▲ 122.0%
Free cash flow: £6.4B; ▲ 24.0%
Operating margin: 24.3%; +11.5 pts
Cash & investments: £3.4B; –
Total debt: £17.7B; ▲ 4.3%
Diluted EPS: £1.39; ▲ 123.2%
Return on equity: 38.0%; –

Trends

Annual figures as reported. Hover a bar or point for the exact value.

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Revenue and net income

RevenueNet income

Margins

Statements

The last 5 fiscal years from the company's annual reports.

GBP millions; negative values in parentheses.

Fiscal year	FY21	FY22	FY23	FY24	FY25
Revenue	24,696	29,324	30,328	31,376	32,667
Cost of revenue	8,163	9,554	8,565	9,048	9,017
Gross profit	16,533	19,770	21,763	22,328	23,650
Research & development	5,019	5,488	6,223	6,401	7,525
Selling, general & admin	7,070	8,372	9,385	11,015	9,088
Operating income	4,357	6,433	6,745	4,021	7,932
Interest expense	769	879	792	669	701
Pre-tax income	3,599	5,628	6,064	3,477	7,401
Income tax	83	707	756	526	1,112
Net income	4,385	14,956	4,928	2,575	5,716
Diluted EPS	£1.08	£3.66	£1.20	£0.62	£1.39
Diluted shares (millions)	4,052	4,084	4,111	4,142	4,117

5 older years available with the 10-year history. Essential plan, from €8.25/month →

Risk checks

Altman Z'' score

1.38 Grey zone

Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.

Piotroski F-score

9/9

Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.

Positive net income: passed
Positive operating cash flow: passed
Return on assets improved: passed
Cash flow exceeds net income: passed
Long-term debt ratio fell: passed
Current ratio improved: passed
No share dilution: passed
Gross margin improved: passed
Asset turnover improved: passed

Sources

20-FPeriod ending Dec 31, 2025Filed Mar 6, 2026Open the report ↗
20-FPeriod ending Dec 31, 2024Filed Mar 3, 2025Open the report ↗
20-FPeriod ending Dec 31, 2023Filed Mar 5, 2024Open the report ↗
20-FPeriod ending Dec 31, 2022Filed Mar 10, 2023Open the report ↗

All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works

Latest annual report: Dec 31, 2025 · Data updated Mar 6, 2026